Glenmark’s Ryaltris Close To Entry In Major Eastern Europe Market

Indian Firm Has Launched Already In Ukraine, Australia And South Africa

Having divested a basket of allergy treatments in Russia and the CIS to Dr Reddy’s last year, Glenmark is gearing up to launch its novel Ryaltris nasal spray in a major Eastern Europe market.

Russia_Night
Ryaltris is under review with the US FDA, as well as regulators across Europe, Canada and Brazil. • Source: Shutterstock

Glenmark is continuing to build up steam for the firm’s Ryaltris (olopatadine hydrochloride/mometasone furoate) 665mcg/25mcg nasal spray after receiving an approval for the product from the Ministry of Health of the Russian Federation.

With the approval in hand, the Indian firm believes launch in Russia is possible in the three-month period ending 30...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

More from Generics Bulletin